In this presentation, Dr. James Sligh, MD, PhD shares why more than 56,000 DecisionDx-Melanoma tests have been ordered to better inform management plan decisions surrounding Stage I-III melanoma patients.
The Majority of Melanoma-Related Deaths Occur in Stage I-II Patients Thought to be low risk
DecisionDx-Melanoma, a molecular diagnostic test for melanoma, provides actionable information, independent of traditional staging factors with significant risk stratification for patients with Class 1A (low risk) and Class 2B (high risk) results.
Did you know?
Search Results